Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use

[1] Diop OM(2015)Introduction of inactivated poliovirus vaccine and switch from trivalent to bivalent oral poliovirus vaccine – worldwide, 2013–2016 MMWR Morb Mortal Wkly Rep 64 669-702

[2] Burns CC(2015)Centers for Disease C, Prevention: Update on Vaccine-Derived Polioviruses - Worldwide, January 2014-March 2015 MMWR Morb Mortal Wkly Rep 64 640-646

[3] Sutter RW(2013)Review: Oral Poliovirus Vaccine Evolution and Insights Relevant to Modeling the Risks of Circulating Vaccine-Derived Polioviruses (cVDPVs) Risk Anal 23 680-702

[4] Wassilak SG(2005)Vaccine-derived polioviruses and the endgame strategy for global polio eradication Annu Rev Microbiol 59 587-635

[5] Kew OM(2014)Modeling the dynamics of oral poliovirus vaccine cessation J Infect Dis 210 S475-S484

[6] Duintjer Tebbens RJ(2014)Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation J Infect Dis 210 S485-S497

[7] Pallansch MA(2015)An economic analysis of poliovirus risk management policy options for 2013–2052 BMC Infect Dis 15 389-913

[8] Kim J-H(2015)Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs BMC Infect Dis 15 379-749

[9] Burns CC(2013)Frequent exposure to suboptimal temperatures in vaccine cold-chain system in India: results of temperature monitoring in 10 states Bull World Health Organ 91 906-605

[10] Kew OM(2013)Characterizing poliovirus transmission and evolution: Insights from modeling experiences with wild and vaccine-related polioviruses Risk Anal 23 703-646

[1] Diop OM(2015)Introduction of inactivated poliovirus vaccine and switch from trivalent to bivalent oral poliovirus vaccine – worldwide, 2013–2016 MMWR Morb Mortal Wkly Rep 64 669-702

[2] Burns CC(2015)Centers for Disease C, Prevention: Update on Vaccine-Derived Polioviruses - Worldwide, January 2014-March 2015 MMWR Morb Mortal Wkly Rep 64 640-646

[3] Sutter RW(2013)Review: Oral Poliovirus Vaccine Evolution and Insights Relevant to Modeling the Risks of Circulating Vaccine-Derived Polioviruses (cVDPVs) Risk Anal 23 680-702

[4] Wassilak SG(2005)Vaccine-derived polioviruses and the endgame strategy for global polio eradication Annu Rev Microbiol 59 587-635

[5] Kew OM(2014)Modeling the dynamics of oral poliovirus vaccine cessation J Infect Dis 210 S475-S484

[6] Duintjer Tebbens RJ(2014)Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation J Infect Dis 210 S485-S497

[7] Pallansch MA(2015)An economic analysis of poliovirus risk management policy options for 2013–2052 BMC Infect Dis 15 389-913

[8] Kim J-H(2015)Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs BMC Infect Dis 15 379-749

[9] Burns CC(2013)Frequent exposure to suboptimal temperatures in vaccine cold-chain system in India: results of temperature monitoring in 10 states Bull World Health Organ 91 906-605

[10] Kew OM(2013)Characterizing poliovirus transmission and evolution: Insights from modeling experiences with wild and vaccine-related polioviruses Risk Anal 23 703-646